Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients (CLOTT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01890044|
Recruitment Status : Withdrawn (Never proceeded with trial. Failure initiate protocol among other centers.)
First Posted : July 1, 2013
Last Update Posted : June 22, 2016
|Condition or disease|
|Venous Thromboembolism Pulmonary Embolus Deep Vein Thrombosis|
Show Detailed Description
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||0 participants|
|Target Follow-Up Duration:||30 Days|
|Official Title:||Consortium of Leaders in the Study Of Traumatic Thromboembolism (CLOTT)|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||October 2016|
|Estimated Study Completion Date :||October 2016|
Moderate to highest risk for VTE
Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
- Venous Thromboembolism (VTE) [ Time Frame: 30 Days from time of hospital admission ]VTE is the clinical spectrum of disease including Deep Vein Thrombosis (DVT) and Pulmonary Embolus.
- Complications following VTE care [ Time Frame: 30 days from date of hospital addmission ]The standard prophylaxis of, and care for diagnosed VTE disease in trauma patients involves medications and devices which themselves have inherent risk. These risks/possible complications include: Death, bleeding, heparin induced thrombocytopenia, and complications associated with the insertion or removal of inferior vena caval filters.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01890044
|United States, California|
|Scripps Mercy Hospital|
|San Diego, California, United States, 92103|
|Principal Investigator:||Steven R Shackford, MD||Scripps Health|